BEIJING, Oct. 19, 2016 /PRNewswire/ -- Sinovac
Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, today provided
an update on the Company's pipeline vaccines.
Sabin-inactivated polio vaccine (sIPV) -- The
Company initiated the phase I clinical trial in October 2016. The phase I trial is designed to
assess the safety and tolerance of the vaccine candidates. Subjects
include adults aged 18-49 years old, young children aged 6-12 years
old, and infants aged two months old for a total of 108 volunteers.
The phase II trial is expected to be launched after the preliminary
results of phase I trials are available. For Phase II, 600 infants
(aged two months old) are expected to be enrolled to select the
objective dosage and assess immunogenicity with a blinded,
randomized and controlled design. The phase II clinical trial is
expected to be completed in the third quarter of 2017. The phase
III clinical trial is expected to assess the immunogenicity and
safety with the vaccine candidate of the selected dosage from the
phase II trial. Sinovac originally obtained approval for sIPV
clinical trials in December 2015.
Varicella vaccine -- The Company completed the phase I
clinical trial in Henan Province
with results showing that the varicella vaccine candidate has a
good safety profile. In the third quarter of 2016, the Company
initiated the phase III clinical trial, which measures efficacy and
immunogenicity with a randomized, double-blind, parallel-treatment,
placebo-controlled study in addition to safety. Over 6,000 subjects
aged from one to twelve years old have been enrolled as volunteers
for the phase III clinical trial. Sinovac obtained approval to
commence human clinical trials in 2015.
Mr. Weidong Yin, Chairman,
President and CEO of Sinovac commented, "We are pleased to provide
an update on the advancement of our vaccine pipeline, which
underscores our strong R&D capabilities and future growth
prospects. As we progress closer towards development and
commercialization, our varicella vaccine and sIPV are expected to
contribute to our domestic and overseas expansion
efforts. With our existing commercial vaccines as well as the
advancement of our pipeline products, we are confident Sinovac will
continue to expand its vaccine portfolio and overall market
position."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac's
newly developed innovative vaccine against HFMD caused by EV71 is
ready for market launch. The Company is currently developing a
number of new products including a Sabin-strain inactivated polio
vaccine, pneumococcal polysaccharides vaccine, pneumococcal
conjugate vaccine and varicella vaccine. Sinovac primarily sells
its vaccines in China, while also
exploring growth opportunities in international markets. The
Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the
Philippines, and was recently granted a license to
commercialize its influenza vaccine in Guatemala. For more information, please visit
the Company's website at www.sinovac.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward looking
statements. Factors that might cause such a difference include our
inability to compete successfully in the competitive and rapidly
changing marketplace in which we operate, failure to retain key
employees, cancellation or delay of projects and adverse general
economic conditions in the United
States and internationally. These risks and other factors
include those listed under "Risk Factors" and elsewhere in our
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue," or the negative
of these terms or other comparable terminology. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. The Company assumes no
obligation to update the forward-looking information contained in
this release.
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-product-pipeline-news-300347361.html
SOURCE Sinovac Biotech Ltd.